Focus Partners Advisor Solutions LLC Has $2.10 Million Stock Position in IQVIA Holdings Inc. $IQV

Focus Partners Advisor Solutions LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 51.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 9,336 shares of the medical research company’s stock after purchasing an additional 3,152 shares during the period. Focus Partners Advisor Solutions LLC’s holdings in IQVIA were worth $2,104,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in IQV. Boston Partners acquired a new stake in shares of IQVIA in the 3rd quarter valued at $676,698,000. Norges Bank acquired a new stake in shares of IQVIA in the 4th quarter valued at $497,445,000. AQR Capital Management LLC increased its stake in shares of IQVIA by 130.2% in the 2nd quarter. AQR Capital Management LLC now owns 1,555,298 shares of the medical research company’s stock valued at $245,099,000 after buying an additional 879,701 shares during the period. JPMorgan Chase & Co. grew its stake in shares of IQVIA by 16.2% during the fourth quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company’s stock worth $856,468,000 after purchasing an additional 528,753 shares during the period. Finally, Citigroup Inc. grew its stake in shares of IQVIA by 108.2% during the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after purchasing an additional 475,557 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Morgan Stanley set a $225.00 price objective on IQVIA in a research note on Thursday, May 7th. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. Mizuho set a $215.00 price objective on IQVIA in a research note on Monday, February 23rd. TD Cowen raised IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, HSBC set a $210.00 price objective on IQVIA in a research note on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $224.13.

IQVIA Stock Performance

IQV stock opened at $182.28 on Thursday. The business’s 50-day moving average price is $173.18 and its two-hundred day moving average price is $194.08. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The firm has a market cap of $30.42 billion, a PE ratio of 22.59, a P/E/G ratio of 1.60 and a beta of 1.21. IQVIA Holdings Inc. has a 1-year low of $153.01 and a 1-year high of $247.04.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. The firm had revenue of $4.15 billion for the quarter, compared to analyst estimates of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company’s revenue for the quarter was up 8.4% on a year-over-year basis. During the same period in the previous year, the company posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA announced that its Board of Directors has approved a share repurchase plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.